- Details
- Sam Chang joins Ashish Kamat to discuss strategies for clinical trials and patient selection required in the face of the world-wide shortage of BCG. Biographies: Sam S. Chang, MD, MBA , Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt University Medical Center, Department of Urology Ashish Kamat, MD, MBBS Professor of Urology and Wayne B. Dudd...
|
- Details
- Joshua Meeks joins Ashish Kamat in discussing the most recent relevant research papers in bladder cancer. Together they explore the publications on checkpoint inhibitors, the use of The Cancer Genome Atlas, Enhanced Recovery after Cystectomy and the impact of blue light flexible cystoscopy with CYSVIEW. Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor of Urology and Biochemistry and Mole...
|
- Details
- Ashish Kamat welcomes a fellow bladder cancer colleague, John Taylor, to discuss international research partnerships among clinicians and organizations. Taylor and Kamat both were essential in the founding of the Leo & Anne Albert Institute of Bladder Cancer Cancer and Research, which provides a platform for clinicians to collaborate on the most recent bladder cancer research. Dr. Taylor also shar...
|
- Details
- Matt Galsky joins Ashish Kamat at ASCO GU 2020 to discuss the most recent advancements in the field of adjuvant therapy in bladder cancer. Together they discuss immune checkpoint blockade therapy in bladder cancer, how to factor in prior therapy for patients considering adjuvant therapy, and Dr. Galsky’s personal research on pathologic complete response. Biography: Matthew Galsky, MD Director of G...
|
- Details
- Joining Ashish Kamat is Arjun Balar, both experts in the field of bladder cancer and each closely involved with the FDA approval of pembrolizumab in the BCG-unresponsive bladder cancer population. Dr. Balar outlines the history of the drug, how the study which led to the FDA approval in NMIBC was designed. Dr. Balar also expands in his approach to counseling his patients who are considering pembro...
|
- Details
- Alicia Morgans and Joshua Meeks discuss the recent advancements in treating Bacille Calmette-Guérin (BCG) unresponsive bladder cancer that came from the 2019 meeting of the Society of Urologic Oncology. They review the many promising clinical trials including some early data from the Phase III VICINIUM trial as well as a promising combination intravesical chemotherapy options for non-muscle-invasi...
|
- Details
- Arjun Balar and Alicia Morgans discuss the new era in systemic therapies in non-muscle invasive bladder cancer (NMIBC) focusing on the systemic checkpoint inhibitor, pembrolizumab that resulted in the US FDA approval of pembrolizumab for treatment in early bladder cancer. Historically being in the domain of urologic oncologists, Drs. Morgans and Balar discuss the importance of the medical oncologi...
|
- Details
- Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC). In this video presentation, Badrinath Konety overviews this study which aimed to evaluate the performance of Cxbladder and urine cytology and Cxbladder's adjudication of atypical cytology and e...
|
- Details
- Yair Lotan discusses the recently published consensus statement on flexible blue light cystoscopy (BLC™) with Cysview ® . His presentation is centered around the published consensus in Nature Reviews developed by multiple experts (authors) in bladder cancer. Yair discusses the role of blue light flexible cystoscopy with CYSVIEW in non-muscle invasive bladder cancer. The expert consensus group met...
|
- Details
- Sia Daneshmand discusses a study published in European Urology which evaluated the atypical cytologies to evaluate the performance of Cxbladder diagnostic tests to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma. Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information. Biography: Siamak (Sia) Daneshmand,...
|
